Vivo Capital

Selected news for the capital firm - Vivo Capital, collected since 11/2017. Recent stories appear in Business Insider and zolmax.com. This capital firm shares healthcare news with Preventice, Preventice Solutions, Biotech, OrbiMed and dozens of others.

Please provide a valid email address.
Shares Healthcare News With (link):
Healthcare Topics
Companies

Selected Headlines

Date Headline (link) Source Relevant Snippet
... opportunity presented by the development of FT218 is increasingly being recognized by the investment community, as we completed in February 2020 a $65 million private placement priced at-the-market with leading biotech investors, Vivo Capital , Avoro Capital Advisors, RTW Investments, Venrock Healthcare Capital Partners, Acuta Capital, and KVP Capital.” “Looking ahead, we have several near-term clinical milestones, including the last patient last visit for the pivotal Phase 3 ...
YANTAI, China , April 2, RemeGen recently announced the closing of approximately USD $100 million in a private financing co-led by Lilly Asia Ventures and Lake Bleu Capital. This round of investment is supported by well-known global institutional investors such as Vivo Capital , Janchor Partners, OrbiMed, Hudson Bay Capital and the company's existing investors. Loyal Valley Capital and China Reform Conson Soochow Overseas Fund also invested through the purchase ...
... repair damaged tissue or fight disease. The startup raised the $150.5 million in a Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital , according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma ...
... repair damaged tissue or fight disease. The startup raised the $150.5 million in a Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital , according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma ...
... repair damaged tissue or fight disease. The startup raised the $150.5 million in a Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital , according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma ...
... round was led by Sofinnova Investments with participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital , Pivotal bioVenture Partners and others. As part of the financing, Jason Pitts, Ph.D., principal at Sofinnova Investments, joins the company's board. He said: “We believe Bolt is well-positioned to execute on its vision ...
Preventice Solutions Announces $137 Million Series B Financing Led by Vivo Capital Company Sees Record Growth for Its Technology Powered by Deep Learning and Artificial Intelligence News provided by Jul 15, 2020, 09:30 ET Share this article MINNEAPOLIS , July 15, 2020 /PRNewswire/ -- Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), today announced that it has raised $137M ...
... comes to life with $30 million to discover and develop new medicines for neurodegenerative and aging-related diseases that target neuroinflammation through a key metabolic pathway. The capital, drawn from Remiges Ventures, SR One, Vivo Capital , Hillsborough Venture and Correlation Ventures, will bankroll the preclinical development of Tranquis’ lead program and expand its platform and pipeline. “We’re focused on a novel approach that targets myeloid immune cell dysfunction,” Tranquis CEO ...
CFO $100,000 Further dealing disclosures will be made in accordance with MAR in respect of the above transactions by Persons Discharging Managerial Responsibility (PDMR). Related Party Transactions As of July 15, 2020, Novo Holdings A/S and Vivo Capital held approximately 11.63 per cent and 11.21 per cent, respectively, of Verona Pharma’s issued ordinary share capital and as such each is considered to be a related party of the Company ...
Preventice Solutions Announces $137 Million Series B Financing Led by Vivo Capital Company Sees Record Growth for Its Technology Powered by Deep Learning and Artificial Intelligence News provided by Jul 15, 2020, 09:30 ET Share this article MINNEAPOLIS , July 15, 2020 /PRNewswire/ -- Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), today announced that it has raised $137M ...
Preventice Solutions Announces $137 Million Series B Financing Led by Vivo Capital Company Sees Record Growth for Its Technology Powered by Deep Learning and Artificial Intelligence News provided by Jul 15, 2020, 09:30 ET Share this article MINNEAPOLIS , July 15, 2020 /PRNewswire/ -- Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), today announced that it has raised $137M ...
... round was led by Sofinnova Investments with participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital , Pivotal bioVenture Partners and others. As part of the financing, Jason Pitts, Ph.D., principal at Sofinnova Investments, joins the company's board. He said: “We believe Bolt is well-positioned to execute on its vision ...
Preventice Solutions Announces $137 Million Series B Financing Led by Vivo Capital Company Sees Record Growth for Its Technology Powered by Deep Learning and Artificial Intelligence News provided by Jul 15, 2020, 09:30 ET Share this article MINNEAPOLIS , July 15, 2020 /PRNewswire/ -- Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), today announced that it has raised $137M ...
... new investors RA Capital Management, Access Biotechnology, Perceptive Advisors, Acorn Bioventures, PBM Capital, Samsara BioCapital, Foresite Capital, Sphera, Fairmount and Soleus Capital, as well as additional investors. Existing investors, OrbiMed, New Enterprise Associates (NEA), Vivo Capital , Abingworth, Novo Holdings A/S, Polar Capital and Aisling Capital also participated. Jefferies LLC (“Jefferies”) is acting as the lead placement agent to the Company in connection with the Financing. Verona Pharma intends to ...
... new investors RA Capital Management, Access Biotechnology, Perceptive Advisors, Acorn Bioventures, PBM Capital, Samsara BioCapital, Foresite Capital, Sphera, Fairmount and Soleus Capital, as well as additional investors. Existing investors, OrbiMed, New Enterprise Associates (NEA), Vivo Capital , Abingworth, Novo Holdings A/S, Polar Capital and Aisling Capital also participated. Jefferies LLC (“Jefferies”) is acting as the lead placement agent to the Company in connection with the Financing. Verona Pharma intends to ...
... Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital , Pivotal bioVenture Partners and others. Bolt is pioneering a new category of immunotherapies that combine the precision of antibody targeting with the power of the innate immune system via activating myeloid cells and reprogramming ...
... round was led by Sofinnova Investments with participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital , Pivotal bioVenture Partners and others. As part of the financing, Jason Pitts, Ph.D., principal at Sofinnova Investments, joins the company's board. He said: “We believe Bolt is well-positioned to execute on its vision ...
... gross proceeds of the Offering) and other estimated offering expenses. Existing investors participated in the financing along with new investors Pfizer Inc. (NYSE: PFE ), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital . ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. Such proceeds ...
... based company that helps doctors grow their practice, announced today that it raised $50 million in a Series C funding round. HLM Venture Partners led the round with participation from new investors Commonfund and Vivo Capital , as well as existing investors Toba Capital, Transformation Capital, and Silicon Valley Bank. Along with the funding announcement, PatientPop added HLM partner Steve Tolle, Vivo Capital principal Nathan Dau, and former cofounder and CEO ...
... based company that helps doctors grow their practice, announced today that it raised $50 million in a Series C funding round. HLM Venture Partners led the round with participation from new investors Commonfund and Vivo Capital , as well as existing investors Toba Capital, Transformation Capital, and Silicon Valley Bank. Along with the funding announcement, PatientPop added HLM partner Steve Tolle, Vivo Capital principal Nathan Dau, and former cofounder and CEO ...